Entecavir in Severe Acute Hepatitis B

An estimated 350 million persons worldwide are chronically infected with HBV [1]. The average estimated carrier rate of Hepatitis B Virus (HBV) in India is 4%, with a total pool of approximately 36 million carriers. Most of India’s carrier pool is established in early childhood, predominantly by horizontal spread due to crowded living conditions and poor hygiene. Acute and subacute liver failure is common complications of viral hepatitis in India and HBV is reckoned to be the etiological agent in 42% and 45% of adult cases, respectively. In conclusion, hepatitis B is a major public health problem in India and will continue to be until appropriate nationwide vaccination programmes and other control measures are established.

• Publication year

  2014

• Venue

  Journal of Liver

• Publication date

  2014-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.4172/2167-0889.1000149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis B vaccine

  2022cited by this paper
• The Study of Efficacy of Lamivudine in Patients with Severe Acute Hepatitis B

  2010influential reference
• Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.

  2009cited by this paper
• Hepatitis B-Associated Acute Liver Failure: Immediate Treatment with Entecavir Inhibits Hepatitis B Virus Replication and Potentially Its Sequelae

  2009cited by this paper
• Entecavir to treat severe acute hepatitis B

  2009cited by this paper
• Lamivudine treatment for severe acute HBV hepatitis

  2008cited by this paper
• Akute Hepatitis B - Ist eine antivirale Therapie indiziert?

  2008cited by this paper
• [Acute hepatitis B: is antiviral therapy indicated? Two case reports].

  2008cited by this paper
• [Lamivudine therapy in patients with severe acute hepatitis B].

  2007cited by this paper
• Management of hepatitis B: Summary of a clinical research workshop

  2007cited by this paper
• A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

  2007cited by this paper
• Hepatitis B e Antigen Negative Chronic Hepatitis in Indian Patients : A Reality.

  2007cited by this paper
• A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B.

  2007cited by this paper
• Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection

  2007cited by this paper
• Cross-Study Analysis of the Relative Efficacies of Oral Antiviral Therapies for Chronic Hepatitis B Infection in Nucleoside-Naive Patients

  2007cited by this paper
• A randomized controlled trial of lamivudine to treat acute hepatitis B

  2007cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.

  2006cited by this paper
• Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

  2006influential reference
• A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

  2005cited by this paper
• Current treatment of chronic hepatitis B: benefits and limitations.

  2005cited by this paper
• Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection?

  2004cited by this paper
• Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes

  2004cited by this paper
• Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

  2004cited by this paper
• Lamivudine treatment for acute severe hepatitis B: a pilot study

  2004cited by this paper
• Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B.

  2002cited by this paper
• Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

  2002cited by this paper
• Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.

  2002cited by this paper
• Hepatitis B--an important public health issue.

  2001cited by this paper
• High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology.

  2001cited by this paper
• Hepatitis B e antigen–negative chronic hepatitis B

  2001cited by this paper
• Management of hepatitis B: 2000--summary of a workshop.

  2001influential reference
• Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies

  2001cited by this paper
• Lamivudine in the treatment of acute hepatitis B.

  2000cited by this paper
• The pilot study.

  2000cited by this paper
• Strategies to prevent and control hepatitis B and C virus infections: a global perspective.

  1999cited by this paper
• Prognostic Evaluation of Early Indicators in Fulminant Hepatic Failure by Multivariate Analysis

  1998cited by this paper
• The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence.

  1998cited by this paper
• In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir

  1998cited by this paper
• Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

  1997cited by this paper
• Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon‐γ: abrogation of immune response defect to a T‐cell‐dependent antigen

  1996cited by this paper
• Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation

  1996cited by this paper
• Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome

  1996cited by this paper
• Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load.

  1994cited by this paper
• High levels of viral replication during acute hepatitis B infection predict progression to chronicity

  1994cited by this paper
• Acute liver failure: redefining the syndromes.

  1993influential reference
• Clinical aspects of hepatitis B virus infection.

  1993cited by this paper
• Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis.

  1993cited by this paper
• Hepatitis B virus and apparent fulminant non-A, non-B hepatitis.

  1992cited by this paper
• Hepatitis B virus.

  1991cited by this paper
• Early indicators of prognosis in fulminant hepatic failure.

  1989cited by this paper
• Hepatitis B virus. The major etiology of hepatocellular carcinoma

  1988cited by this paper
• Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.

  1987cited by this paper
• Age‐ and sex‐related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal)

  1987cited by this paper
• Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.

  1985cited by this paper
• [Subacute hepatic failure].

  1984cited by this paper
• Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.

  1983cited by this paper
• Influence of delta infection on severity of hepatitis B.

  1982cited by this paper
• Incidence of hepatitis B virus infections in preschool children in Taiwan.

  1982cited by this paper
• SURVIVAL OF HEPATITIS B VIRUS AFTER DRYING AND STORAGE FOR ONE WEEK

  1981cited by this paper
• Two distinct types of hepatitis in experimental hepatitis B virus infection.

  1980cited by this paper
• Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages

  1976cited by this paper

• No citing papers are available for this paper.